Discontinued — last reported Q4 '24
STERIS Life Science Member — Segment operating income increased by 8.3% to $58.13M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 2.5%, from $56.74M to $58.13M. This is a positive signal — higher values indicate stronger performance for this metric.
Higher values indicate strong segment-level profitability and effective management of costs and revenues.
This metric represents the final operating income for the Life Science segment after accounting for all relevant segment...
Standard segment operating income metric used across all public companies to report divisional performance.
ste_segment_life_science_member_segment_operating_income| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $49.09M | $57.52M | $52.03M | $55.31M | $48.62M | $45.25M | $49.84M | $50.28M | $56.74M | $52.58M | $53.70M | $58.13M |
| QoQ Change | — | +17.2% | -9.5% | +6.3% | -12.1% | -6.9% | +10.1% | +0.9% | +12.8% | -7.3% | +2.1% | +8.3% |
| YoY Change | — | — | — | +12.7% | -15.5% | -13.0% | -9.9% | +3.4% | +25.4% | +5.5% | +6.8% | +2.5% |